Survival Of Subjects With Chronic Obstructive Pulmonary Disease (COPD)

• Status: Completed
• Trial end date: 2005-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to see if fluticasone 500mcg/salmeterol 50mcg can improve the survival of subjects with COPD and also assess the long term safety profile of this drug.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Fluticasone; Salmeterol Xinafoate; Xhance

Criteria

Inclusion criteria:

• Patients with COPD and FEV1 <60% of predicted normal and baseline (pre-bronchodilator) FEV1/FVC ratio <70%.

• Current or ex-smokers with a smoking history of at least 10 pack-years.

Exclusion criteria:

• Diagnosis of other respiratory disorders (including asthma).

• Requirement for long term oxygen therapy.